These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11471565)

  • 1. The use of ribozyme gene therapy for the inhibition of HIV replication and its pathogenic sequelae.
    Rigden JE; Ely JA; Macpherson JL; Gerlach WL; Sun LQ; Symonds GP
    Curr Issues Mol Biol; 2000 Apr; 2(2):61-9. PubMed ID: 11471565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribozymes in gene therapy of HIV-1.
    Macpherson JL; Ely JA; Sun LQ; Symonds GP
    Front Biosci; 1999 Jun; 4():D497-505. PubMed ID: 10352136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-HIV ribozymes.
    Sun LQ; Ely JA; Gerlach W; Symonds G
    Mol Biotechnol; 1997 Jun; 7(3):241-51. PubMed ID: 9219238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside.
    Zeller SJ; Kumar P
    Yale J Biol Med; 2011 Sep; 84(3):301-9. PubMed ID: 21966049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV and Ribozymes.
    Scarborough RJ; Gatignol A
    Adv Exp Med Biol; 2015; 848():97-116. PubMed ID: 25757617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The application of ribozymes to HIV infection.
    Rossi JJ
    Curr Opin Mol Ther; 1999 Jun; 1(3):316-22. PubMed ID: 11713796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model.
    Bai J; Banda N; Lee NS; Rossi J; Akkina R
    Mol Ther; 2002 Dec; 6(6):770-82. PubMed ID: 12498773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and testing of retroviral vectors expressing multimeric hammerhead ribozymes targeted against all major clades of HIV-1.
    Ramezani A; Ma XZ; Nazari R; Joshi S
    Front Biosci; 2002 Feb; 7():a29-36. PubMed ID: 11815297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribozymes: use as anti-HIV therapeutic molecules.
    Dropulic B; Elkins DA; Rossi JJ; Sarver N
    Antisense Res Dev; 1993; 3(1):87-94. PubMed ID: 8495108
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection.
    Morris KV; Rossi JJ
    Curr HIV Res; 2004 Apr; 2(2):185-91. PubMed ID: 15078182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of an anti-HIV-1 combination gene therapy strategy using the antisense RNA and multimeric hammerhead ribozymes.
    Ramezani A; Ma XZ; Ameli M; Arora A; Joshi S
    Front Biosci; 2006 Sep; 11():2940-8. PubMed ID: 16720366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human immunodeficiency virus type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line.
    Michienzi A; Conti L; Varano B; Prislei S; Gessani S; Bozzoni I
    Hum Gene Ther; 1998 Mar; 9(5):621-8. PubMed ID: 9551610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribozymes: killing the messenger.
    Barinaga M
    Science; 1993 Dec; 262(5139):1512-4. PubMed ID: 8248799
    [No Abstract]   [Full Text] [Related]  

  • 14. The hairpin ribozyme: discovery, two-dimensional model, and development for gene therapy.
    Hampel A
    Prog Nucleic Acid Res Mol Biol; 1998; 58():1-39. PubMed ID: 9308362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy.
    Bai J; Rossi J; Akkina R
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):385-99. PubMed ID: 11282007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites.
    Hotchkiss G; Maijgren-Steffensson C; Ahrlund-Richter L
    Mol Ther; 2004 Jul; 10(1):172-80. PubMed ID: 15233952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients.
    Amado RG; Mitsuyasu RT; Rosenblatt JD; Ngok FK; Bakker A; Cole S; Chorn N; Lin LS; Bristol G; Boyd MP; MacPherson JL; Fanning GC; Todd AV; Ely JA; Zack JA; Symonds GP
    Hum Gene Ther; 2004 Mar; 15(3):251-62. PubMed ID: 15018734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunodeficiency virus type I as a target for gene therapy.
    Gottfredsson M; Bohjanen PR
    Front Biosci; 1997 Dec; 2():d619-34. PubMed ID: 9388165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1.
    Yamada O; Kraus G; Luznik L; Yu M; Wong-Staal F
    J Virol; 1996 Mar; 70(3):1596-601. PubMed ID: 8627679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA enzymes (ribozymes) as antiviral therapeutic agents.
    Rossi JJ; Sarver N
    Trends Biotechnol; 1990 Jul; 8(7):179-83. PubMed ID: 1366622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.